Suzhou’s CStone Pharma has filed for a Hong Kong IPO. Founded in 2015, CStone has quickly built a portfolio of 14 oncology candidates. The company says its three core products are IO drugs — PD-1, PD-L1 and CTLA-4 antibodies — which will be paired with other of its assets to offer combination therapies. As part of its development, CStone has in-licensed molecularly targeted compounds from Agios (a $424 million deal) and Blueprint (a $386 million, three-drug agreement), which CStone will develop in greater China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!